U.S. Markets open in 2 hrs 42 mins

Albany Molecular Research, Inc. (AYM.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
17.9180.000 (0.000%)
As of 9:08AM CEST. Market open.
Full screen
Previous Close17.918
Open0.000
Bid0.000 x 26300
Ask0.000 x 25300
Day's Range0.000 - 0.000
52 Week Range
Volume20
Avg. Volume1
Market Cap776.89M
BetaN/A
PE Ratio (TTM)-12.63
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journalslast month

    AMRI shareholders approve sale of company

    Shareholders of Albany Molecular Research Inc. on Friday approved the sale of the pharmaceutical research company to affiliates of private-equity firms based in Chicago and Washington, D.C. The vote comes a little more than two months after the drug developer's board unanimously approved the sale of the AMRI to affiliates of The Carlyle Group and GTCR LLC . The private-equity firms have agreed to pay $21.75 per share, an equivalent of more than $900 million to purchase the Albany, New York, region's third-largest public company.

  • Reuters4 months ago

    GTCR, Carlyle to buy contract research firm Albany Molecular

    Contract drug manufacturer and research company Albany Molecular Research Inc said on Tuesday it had agreed to be taken private by buyout firms Carlyle Group LP and GTCR LLC for about $922 million in cash. Clinical research organizations can prove to be lucrative investments for private equity firms.

  • 24/7 Wall St.4 months ago

    Why Albany Molecular Is Actually Getting a Very Good Premium

    Shares of Albany Molecular Research saw a handy gain on Tuesday after it was announced that the company signed a definitive agreement to be acquired.